Literature DB >> 16629058

Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy.

K Patel1, R Macharia, H Amthor.   

Abstract

Over the past decade, signalling cascades have been characterised that control key features of muscle growth, including the proliferation, differentiation of muscle precursors, the control cell size (hypertrophy) and cell death. In this review we highlight how two differing signalling molecules, Insulin-like Growth Factor-1 (IGF-1) and myostatin, regulate key steps during muscle development. We discuss how IGF-1 and myostatin signalling cascades can be manipulated to stimulate muscle growth. We summarise experimental data from mdx mouse, the animal model for Duchenne muscular dystrophy, that suggest a therapeutic value of these strategies for patients suffering from muscular dystrophy without redressing the primary cause of the lesion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16629058

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  9 in total

Review 1.  The therapeutic potential of IGF-I in skeletal muscle repair.

Authors:  Yao-Hua Song; Jenny L Song; Patrice Delafontaine; Michael P Godard
Journal:  Trends Endocrinol Metab       Date:  2013-04-27       Impact factor: 12.015

Review 2.  Satellite Cells in Muscular Dystrophy - Lost in Polarity.

Authors:  Natasha C Chang; Fabien P Chevalier; Michael A Rudnicki
Journal:  Trends Mol Med       Date:  2016-05-05       Impact factor: 11.951

3.  Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.

Authors:  Melissa P Wu; Emanuela Gussoni
Journal:  Muscle Nerve       Date:  2011-01       Impact factor: 3.217

4.  Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.

Authors:  Yunxiang Zhu; Ji-Lei Jiang; Nathan K Gumlaw; Jinhua Zhang; Scott D Bercury; Robin J Ziegler; Karen Lee; Mariko Kudo; William M Canfield; Timothy Edmunds; Canwen Jiang; Robert J Mattaliano; Seng H Cheng
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

5.  Tendons of myostatin-deficient mice are small, brittle, and hypocellular.

Authors:  Christopher L Mendias; Konstantin I Bakhurin; John A Faulkner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

Review 6.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

7.  Label-Free LC-MS/MS Proteomics Analyses Reveal Proteomic Changes Accompanying MSTN KO in C2C12 Cells.

Authors:  Lamei Wang; Yu Huang; Xiaolong Wang; Yulin Chen
Journal:  Biomed Res Int       Date:  2019-04-03       Impact factor: 3.411

Review 8.  Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases.

Authors:  Syed Sayeed Ahmad; Khurshid Ahmad; Eun Ju Lee; Yong-Ho Lee; Inho Choi
Journal:  Cells       Date:  2020-07-24       Impact factor: 6.600

9.  The salmonid myostatin gene family: a novel model for investigating mechanisms that influence duplicate gene fate.

Authors:  Casey B Lawson; Takumu Niino; Russell A Hermansen; Vera Brok-Volchanskaya; Melissa F Jackson; Dilip K Garikipati; David A Liberles; Buel D Rodgers
Journal:  BMC Evol Biol       Date:  2012-10-08       Impact factor: 3.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.